Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases.

Authors :: Trivillin VA
Garabalino MA
Colombo LL
González SJ
Farías RO
Monti Hughes A
Pozzi EC
Bortolussi S
Altieri S
Itoiz ME
Aromando RF
Nigg DW
Schwint AE
Source :: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine [Appl Radiat Isot] 2014 Jun; Vol. 88, pp. 94-8. Date of Electronic Publication: 2013 Dec 05.
Publication Year :: 2014
Abstract: BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25-76ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.<br /> (© 2013 Published by Elsevier Ltd.)

Subjects :: Animals
Cell Line, Tumor
Drug Combinations
Lung Neoplasms radiotherapy
Metabolic Clearance Rate
Organ Specificity
Phenylalanine administration & dosage
Phenylalanine pharmacokinetics
Radiotherapy Dosage
Rats
Tissue Distribution
Boron Compounds administration & dosage
Boron Compounds pharmacokinetics
Boron Neutron Capture Therapy methods
Lung Neoplasms metabolism
Lung Neoplasms secondary
Phenylalanine analogs & derivatives

Language :: English
ISSN :: 1872-9800
Volume :: 88
Database :: MEDLINE
Journal :: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
Publication Type :: Academic Journal
Accession number :: 24360862
Full Text :: https://doi.org/10.1016/j.apradiso.2013.11.115

Full Text Access

Tools